Kalexo Bio Overview

  • Year Founded
  • 2023

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

Kalexo Bio General Information

Description

Developer of siRNA therapeutics designed to target the genetic drivers of cardiovascular disease. The company's platform utilizes a dual-targeting approach to simultaneously silence multiple risk factors in a single regimen, enabling patients with dyslipidemia to achieve durable lipid management and prevent atherosclerotic cardiovascular disease events.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1111 Broadway
  • Suite 1300
  • Oakland, CA 94607
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1111 Broadway
  • Suite 1300
  • Oakland, CA 94607
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kalexo Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 17-Sep-2025 Completed Pre-Clinical Trials
To view Kalexo Bio’s complete valuation and funding history, request access »

Kalexo Bio Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aditum Bio Venture Capital Minority
Mabwell Corporation Minority
To view Kalexo Bio’s complete investors history, request access »

Kalexo Bio FAQs

  • When was Kalexo Bio founded?

    Kalexo Bio was founded in 2023.

  • Where is Kalexo Bio headquartered?

    Kalexo Bio is headquartered in Oakland, CA.

  • What industry is Kalexo Bio in?

    Kalexo Bio’s primary industry is Drug Discovery.

  • Is Kalexo Bio a private or public company?

    Kalexo Bio is a Private company.

  • What is Kalexo Bio’s current revenue?

    The current revenue for Kalexo Bio is .

  • Who are Kalexo Bio’s investors?

    Aditum Bio and Mabwell have invested in Kalexo Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process